Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient‐derived primary prostate cells-Reference-Cited by-同舟云学术

Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient‐derived primary prostate cells

Published:2020-08-06 Issue:14 Volume:80 Page:1233-1243
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Naeem Aisha¹²,Dakshanamurthy Sivanesan¹,Walthieu Henry¹,Parasido Erika¹,Avantaggiati Maria¹,Tricoli Lucas³,Kumar Deepak³,Lee Richard J.⁴,Feldman Adam⁴,Noon Muhammad S.⁵,Byers Stephen¹,Rodriguez Olga¹⁶,Albanese Chris¹⁶^ORCID

Affiliation:

1. Department of Oncology, Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington DC

2. Ministry of Public Health Doha Qatar

3. Julius L. Chambers Biomedical/Biotechnology Research Institute North Carolina Central University Durham North Carolina

4. Department of Medicine Massachusetts General Hospital Cancer Center Boston Massachusetts

5. Data Science Institute University of Arizona Tuscon Arizona

6. Center for Translational Imaging Georgetown University Medical Center Washington DC

Funder

National Institutes of Health

U.S. Department of Defense

Publisher

Wiley